Certain R5
virus tropic HIV-1 subjects with
viral load effectively conventionally controlled using HAART, i.e., subject having less than 50 viral copies / mL (<50 cp / mL), may be substantially more susceptible than others to effective monotherapy treatment using anti-CCR5 agents, e.g, PRO 140 mAbs. Certain HIV-1 subjects using PRO 140 monotherapy treatment may experience prolonged or
unlimited time periods with actual undetectable viral loads, extremely low
viral load counts ≤1 cp / mL, very low, or low levels, or at conventionally undetectable levels, during monotherapy. Increasing
dose amounts of anti-CCR5 agents, e.g., PRO 140, from 350 mg to 525 mg or 700 mg, may beneficially suppress a subject's
viral load count before, during, and / or maintain effective prolonged monotherapy and may shorten the period of time necessary to determine if a subject will respond positively to PRO 140 monotherapy to less than eight (8) weeks. This invention includes protocols, methods, and kits.